S. Bowker

Discovery, synthesis and biological evaluation of novel glucokinase activators.

Scott Boyd, G. Currie, B. Hayter, 2005, Bioorganic & medicinal chemistry letters.

Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists.

Hayley S. Brown, D. Laber, James S. Scott, 2014, Journal of medicinal chemistry.

Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes.

Andrew G. Leach, A. Plowright, Robert D. M. Davies, 2012, Bioorganic & medicinal chemistry letters.

Making medicinal chemistry more effective--application of Lean Sigma to improve processes, speed and quality.

Nidhal Selmi, Jan Kihlberg, Magnus J. Johansson, 2009, Drug discovery today.

Identification, optimization, and pharmacology of acylurea GHS-R1a inverse agonists.

Nathaniel G. Martin, Robert D. M. Davies, Alastair J. H. Brown, 2014, Journal of medicinal chemistry.

Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017).

Martin J Packer, Nidhal Selmi, David Hargreaves, 2012, Journal of medicinal chemistry.

Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists.

Andrew G. Leach, Hayley S. Brown, D. Laber, 2014, Journal of medicinal chemistry.